Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities

Objective

To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report.

Methods

Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit’s peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities.

Results

In all, 5,588 users described using BPC-157 and/or TB-500 for a specific musculoskeletal injury, most often a chronic tendon problem of the shoulder, knee or elbow. Only 3.8% of users described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors. The median BPC-157 dose (366 µg per injection) was about 2.7 times the human-equivalent dose of the 10 µg/kg rat regimen, and among new users it rose from 300 µg in 2024 to 500 µg in 2025. Of those stating an outcome, 79.3% reported improvement, and 36.6% of all users were also in physical therapy. Overall, 27.2% described at least one side effect, most often fatigue, anxiety, anhedonia and insomnia. Anhedonia was more common than among users of the four other peptides (10.2% versus 1.3% of those with side effects).

Conclusion

Use of these unapproved peptides for musculoskeletal injury is largely unsupervised, relying on grey-market products at self-selected, rising doses without established safety or efficacy.

What is already known on this topic

• Evidence that BPC-157 and TB-500 help tendon, ligament or muscle injury comes almost entirely from animal studies.

• Both are prohibited in sport by the World Anti-Doping Agency, and in July 2026 a US Food and Drug Administration advisory committee voted to recommend them for pharmacy compounding.

What this study adds

• We analyzed over 90,000 Reddit posts from 5,588 users taking these peptides for a specific injury, most often a chronic tendon problem of the shoulder, knee or elbow.

• Only 3.8% described physician involvement, and 90.9% of those naming a source bought from research-chemical vendors.

• The median BPC-157 dose was about 2.7 times the human-equivalent dose of the rat regimen, and 27.2% of users reported a side effect.

• Anhedonia was about eight times as common as among users of four other peptides in the same communities.

How this study might affect research, practice or policy

• Clinicians treating chronic tendon problems should ask about peptide use and counsel patients on the lack of human efficacy data, unregulated supply, anti-doping status and reported side effects.

• Trials with prespecified neuropsychiatric outcomes are needed before any benefit or dose can be claimed.

• These findings may inform regulatory decisions on pharmacy compounding.